Jay P Mclaughlin

List of Publications by Year
in descending order

82	3,837	136950 32	133252 59
papers	citations	h-index	g-index

84	84	84	3049
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Expression of Human Immunodeficiency Virus Transactivator of Transcription (HIV-Tat1-86) Protein Alters Nociceptive Processing that is Sensitive to Anti-Oxidant and Anti-Inflammatory Interventions. Journal of NeuroImmune Pharmacology, 2022, 17, 152-164.	4.1	8
2	Examination of the Novel Sigma-1 Receptor Antagonist, SI 1/28, for Antinociceptive and Anti-allodynic Efficacy against Multiple Types of Nociception with Fewer Liabilities of Use. International Journal of Molecular Sciences, 2022, 23, 615.	4.1	3
3	Clathrin-nanoparticles deliver BDNF to hippocampus and enhance neurogenesis, synaptogenesis and cognition in HIV/neuroAIDS mouse model. Communications Biology, 2022, 5, 236.	4.4	18
4	An analog of [d-Trp]CJ-15,208 exhibits kappa opioid receptor antagonism following oral administration and prevents stress-induced reinstatement of extinguished morphine conditioned place preference. Pharmacology Biochemistry and Behavior, 2022, 217, 173405.	2.9	1
5	Characterization of CM-398, a Novel Selective Sigma-2 Receptor Ligand, as a Potential Therapeutic for Neuropathic Pain. Molecules, 2022, 27, 3617.	3.8	12
6	HIV-1 Tat and cocaine impact astrocytic energy reservoirs and epigenetic regulation by influencing the LINC01133-hsa-miR-4726-5p-NDUFA9 axis. Molecular Therapy - Nucleic Acids, 2022, 29, 243-258.	5.1	4
7	HIV-1 Tat and cocaine impact mitochondrial epigenetics: effects on DNA methylation. Epigenetics, 2021, 16, 980-999.	2.7	19
8	HIV-Tat and Cocaine Impact Brain Energy Metabolism: Redox Modification and Mitochondrial Biogenesis Influence NRF Transcription-Mediated Neurodegeneration. Molecular Neurobiology, 2021, 58, 490-504.	4.0	24
9	Kratom Alkaloids, Natural and Semi-Synthetic, Show Less Physical Dependence and Ameliorate Opioid Withdrawal. Cellular and Molecular Neurobiology, 2021, 41, 1131-1143.	3.3	36
10	Controlling opioid receptor functional selectivity by targeting distinct subpockets of the orthosteric site. ELife, 2021, 10, .	6.0	40
11	Positive allosteric modulation of the mu-opioid receptor produces analgesia with reduced side effects. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	36
12	In vivo proton magnetic resonance spectroscopy detection of metabolite abnormalities in aged Tat-transgenic mouse brain. GeroScience, 2021, 43, 1851-1862.	4.6	9
13	Development of New Benzylpiperazine Derivatives as Ïƒ₁ Receptor Ligands with in Vivo Antinociceptive and Anti-Allodynic Effects. ACS Chemical Neuroscience, 2021, 12, 2003-2012.	3.5	7
14	Mini review: Promotion of substance abuse in HIV patients: Biological mediation by HIV-1 Tat protein. Neuroscience Letters, 2021, 753, 135877.	2.1	7
15	Kratom Alkaloids as Probes for Opioid Receptor Function: Pharmacological Characterization of Minor Indole and Oxindole Alkaloids from Kratom. ACS Chemical Neuroscience, 2021, 12, 2661-2678.	3.5	20
16	Binge ethanol consumption-associated behavioral impairments in male mice using a gelatin-based drinking-in-the dark model. Alcohol, 2021, 95, 25-36.	1.7	2
17	A Novel Mitragynine Analog with Low-Efficacy Mu Opioid Receptor Agonism Displays Antinociception with Attenuated Adverse Effects. Journal of Medicinal Chemistry, 2021, 64, 13873-13892.	6.4	33
18	Proteomics Profiling with SWATH-MS Quantitative Analysis of Changes in the Human Brain with HIV Infection Reveals a Differential Impact on the Frontal and Temporal Lobes. Brain Sciences, 2021, 11, 1438.	2.3	1

#	Article	IF	Citations
19	Peptide Kappa Opioid Receptor Ligands and Their Potential for Drug Development. Handbook of Experimental Pharmacology, 2021, 271, 197-220.	1.8	5
20	Oxidative Metabolism as a Modulator of Kratomâ€™s Biological Actions. Journal of Medicinal Chemistry, 2021, 64, 16553-16572.	6.4	26
21	Preventing Morphine-Seeking Behavior through the Re-Engineering of Vincamineâ€™s Biological Activity. Journal of Medicinal Chemistry, 2020, 63, 5119-5138.	6.4	30
22	Phenylalanine Stereoisomers of CJ-15,208 and [d-Trp]CJ-15,208 Exhibit Distinctly Different Opioid Activity Profiles. Molecules, 2020, 25, 3999.	3.8	10
23	Lyophilized Kratom Tea as a Therapeutic Option for Opioid Dependence. Drug and Alcohol Dependence, 2020, 216, 108310.	3.2	40
24	Chronic Voluntary Binge Ethanol Consumption Causes Sexâ€Specific Differences in Microglial Signaling Pathways and Withdrawalâ€associated Behaviors in Mice. Alcoholism: Clinical and Experimental Research, 2020, 44, 1791-1806.	2.4	22
25	Discovery of a Highly Selective Sigma-2 Receptor Ligand, 1-(4-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one (CM398), with Drug-Like Properties and Antinociceptive Effects In Vivo. AAPS Journal, 2020, 22, 94.	4.4	33
26	[³H]Dopamine Uptake through the Dopamine and Norepinephrine Transporters is Decreased in the Prefrontal Cortex of Transgenic Mice Expressing HIV-1 Transactivator of Transcription Protein. Journal of Pharmacology and Experimental Therapeutics, 2020, 374, 241-251.	2.5	16
27	Multifunctional opioid receptor agonism and antagonism by a novel macrocyclic tetrapeptide prevents reinstatement of morphineâ€seeking behaviour. British Journal of Pharmacology, 2020, 177, 4209-4222.	5.4	21
28	Region-specific effects of HIV-1 Tat on intrinsic electrophysiological properties of pyramidal neurons in mouse prefrontal cortex and hippocampus. Journal of Neurophysiology, 2020, 123, 1332-1341.	1.8	21
29	Design, Synthesis, and Characterization of the Macrocyclic Tetrapeptide cyclo[Pro-Sar-Phe-<scp>d</scp>-Phe]: A Mixed Opioid Receptor Agonistâ€“Antagonist Following Oral Administration. ACS Chemical Neuroscience, 2020, 11, 1324-1336.	3.5	12
30	Characterization of Sigma 1 Receptor Antagonist CM-304 and Its Analog, AZ-66: Novel Therapeutics Against Allodynia and Induced Pain. Frontiers in Pharmacology, 2019, 10, 678.	3.5	31
31	Antinociceptive activity of thiazole-containing cyclized DAMGO and Leu-(Met) enkephalin analogs. Organic and Biomolecular Chemistry, 2019, 17, 5305-5315.	2.8	10
32	<scp>HIV</scp>â€1 <scp>T</scp>at regulation of dopamine transmission and microglial reactivity is brain region specific. Glia, 2018, 66, 1915-1928.	4.9	13
33	A stable isotope dilution tandem mass spectrometry method of major kavalactones and its applications. PLoS ONE, 2018, 13, e0197940.	2.5	15
34	Selective Îº receptor partial agonist HS666 produces potent antinociception without inducing aversion after i.c.v. administration in mice. British Journal of Pharmacology, 2017, 174, 2444-2456.	5.4	59
35	Conditional Human Immunodeficiency Virus Transactivator of Transcription Protein Expression Induces Depression-like Effects andÂOxidative Stress. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2017, 2, 599-609.	1.5	16
36	A one-pot multicomponent approach to a new series of morphine derivatives and their biological evaluation. Organic and Biomolecular Chemistry, 2017, 15, 7796-7801.	2.8	2

#	Article	IF	Citations
37	Mitragynine/Corynantheidine Pseudoindoxyls As Opioid Analgesics with Mu Agonism and Delta Antagonism, Which Do Not Recruit Î²-Arrestin-2. Journal of Medicinal Chemistry, 2016, 59, 8381-8397.	6.4	229
38	Altered secondary structure of Dynorphin A associates with loss of opioid signalling and NMDA-mediated excitotoxicity in SCA23. Human Molecular Genetics, 2016, 25, ddw130.	2.9	9
39	The cross-talk of HIV-1 Tat and methamphetamine in HIV-associated neurocognitive disorders. Frontiers in Microbiology, 2015, 6, 1164.	3.5	51
40	Didehydro-Cortistatin A Inhibits HIV-1 Tat Mediated Neuroinflammation and Prevents Potentiation of Cocaine Reward in Tat Transgenic Mice. Current HIV Research, 2015, 13, 64-79.	0.5	59
41	Parallel Synthesis of Hexahydrodiimidazodiazepines Heterocyclic Peptidomimetics and Their in Vitro and in Vivo Activities at Î¼ (MOR), Î´ (DOR), and Îº (KOR) Opioid Receptors. Journal of Medicinal Chemistry, 2015, 58, 4905-4917.	6.4	27
42	Synthesis and biological evaluations of novel endomorphin analogues containing Î±-hydroxy-Î²-phenylalanine (AHPBA) displaying mixed Î¼/Î´ opioid receptor agonist and Î´ opioid receptor antagonist activities. European Journal of Medicinal Chemistry, 2015, 92, 270-281.	5.5	16
43	Exposure to HIV-1 Tat in brain impairs sensorimotor gating and activates microglia in limbic and extralimbic brain regions of male mice. Behavioural Brain Research, 2015, 291, 209-218.	2.2	50
44	Synthesis and Characterization of a Dual Kappa-Delta Opioid Receptor Agonist Analgesic Blocking Cocaine Reward Behavior. ACS Chemical Neuroscience, 2015, 6, 1813-1824.	3.5	42
45	HIV-1 Tat Protein Exposure Potentiates Ethanol Reward and Reinstates Extinguished Ethanol-Conditioned Place Preference. Current HIV Research, 2015, 12, 415-423.	0.5	15
46	Estrous Cycle and HIV-1 Tat Protein Influence Cocaine-Conditioned Place Preference and Induced Locomotion of Female Mice. Current HIV Research, 2015, 12, 388-396.	0.5	16
47	Conditional Tat Protein Brain Expression in the GT-tg Bigenic Mouse Induces Cerebral Fractional Anisotropy Abnormalities. Current HIV Research, 2015, 13, 3-9.	0.5	10
48	Effects of Conditional Central Expression of HIV-1 Tat Protein to Potentiate Cocaine-Mediated Psychostimulation and Reward Among Male Mice. Neuropsychopharmacology, 2014, 39, 380-388.	5.4	61
49	Anxiety-like behavior of mice produced by conditional central expression of the HIV-1 regulatory protein, Tat. Psychopharmacology, 2014, 231, 2349-2360.	3.1	62
50	Nonpeptide Small Molecule Agonist and Antagonist Original Leads for Neuropeptide FF1 and FF2 Receptors. Journal of Medicinal Chemistry, 2014, 57, 8903-8927.	6.4	21
51	Progesterone protects normative anxiety-like responding among ovariectomized female mice that conditionally express the HIV-1 regulatory protein, Tat, in the CNS. Hormones and Behavior, 2014, 65, 445-453.	2.1	42
52	Conditional Tat protein expression in the GT-tg bigenic mouse brain induces gray matter density reductions. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 43, 49-54.	4.8	45
53	Central administration of angiotensin IV rapidly enhances novel object recognition among mice. Neuropharmacology, 2013, 70, 247-253.	4.1	23
54	The Macrocyclic Peptide Natural Product CJ-15,208 Is Orally Active and Prevents Reinstatement of Extinguished Cocaine-Seeking Behavior. Journal of Natural Products, 2013, 76, 433-438.	3.0	31

#	Article	IF	Citations
55	Discovery of Novel Antinociceptive Î±-Conotoxin Analogues from the Direct In Vivo Screening of a Synthetic Mixture-Based Combinatorial Library. ACS Combinatorial Science, 2013, 15, 153-161.	3.8	14
56	Inhibition of GÎ²Î³-subunit signaling potentiates morphine-induced antinociception but not respiratory depression, constipation, locomotion, and reward. Behavioural Pharmacology, 2013, 24, 144-152.	1.7	22
57	Physical Presence of Nor-Binaltorphimine in Mouse Brain over 21 Days after a Single Administration Corresponds to Its Long-Lasting Antagonistic Effect onÎ¹-Opioid Receptors. Journal of Pharmacology and Experimental Therapeutics, 2013, 346, 545-554.	2.5	43
58	The macrocyclic tetrapeptide [<scp>D</scp>â€<scp>T</scp>rp]<scp>CJ</scp>â€15,208 produces shortâ€acting Î¹ opioid receptor antagonism in the <scp>CNS</scp> after oral administration. British Journal of Pharmacology, 2013, 169, 426-436.	5.4	37
59	Expression of HIV-Tat protein is associated with learning and memory deficits in the mouse. Behavioural Brain Research, 2012, 229, 48-56.	2.2	121
60	Peptides derived from the prohormone proNPQ/spexin are potent central modulators of cardiovascular and renal function and nociception. FASEB Journal, 2012, 26, 947-954.	0.5	74
61	Opioid peptides: potential for drug development. Drug Discovery Today: Technologies, 2012, 9, e23-e31.	4.0	56
62	Novel opioid cyclic tetrapeptides: Trp isomers of CJâ€15,208 exhibit distinct opioid receptor agonism and shortâ€acting Î¹ opioid receptor antagonism. British Journal of Pharmacology, 2012, 165, 1097-1108.	5.4	45
63	Targeting dynorphin/kappa opioid receptor systems to treat alcohol abuse and dependence. Alcohol, 2012, 46, 359-370.	1.7	94
64	Unexpected Opioid Activity Profiles of Analogues of the Novel Peptide Kappa Opioid Receptor Ligand CJâ€15,208. ChemMedChem, 2011, 6, 1739-1745.	3.2	32
65	Identification of Two Novel, Potent, Low-Liability Antinociceptive Compounds from the Direct In Vivo Screening of a Large Mixture-Based Combinatorial Library. AAPS Journal, 2010, 12, 318-329.	4.4	56
66	Endogenous kappa-opioid mediation of stress-induced potentiation of ethanol-conditioned place preference and self-administration. Psychopharmacology, 2010, 210, 199-209.	3.1	115
67	Synthesis of CJ-15,208, a novel Î¹-opioid receptor antagonist. Tetrahedron Letters, 2010, 51, 5020-5023.	1.4	25
68	Zyklophin, a systemically active selective kappa opioid receptor peptide antagonist with short duration of action. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 18396-18401.	7.1	80
69	Endogenous Î¹ Opioid Activation Mediates Stress-Induced Deficits in Learning and Memory. Journal of Neuroscience, 2009, 29, 4293-4300.	3.6	87
70	Peptide Kappa Opioid Receptor Ligands: Potential for Drug Development. AAPS Journal, 2009, 11, 312-322.	4.4	114
71	Synthesis of Cyclic Tetrapeptide CJ 15,208: A Novel Kappa Opioid Receptor Antagonist. Advances in Experimental Medicine and Biology, 2009, 611, 269-270.	1.6	11
72	Northeast Under/graduate Research Organization for Neuroscience (NEURON): Our Thirteenth Conference for Neuroscience Trainees and Educators. Journal of Undergraduate Neuroscience Education: JUNE: A Publication of FUN, Faculty for Undergraduate Neuroscience, 2009, 7, A65-8.	0.0	2

#	Article	IF	Citations
73	Prior Activation of Kappa Opioid Receptors by U50,488 Mimics Repeated Forced Swim Stress to Potentiate Cocaine Place Preference Conditioning. Neuropsychopharmacology, 2006, 31, 787-794.	5.4	200
74	Social Defeat Stress-Induced Behavioral Responses are Mediated by the Endogenous Kappa Opioid System. Neuropsychopharmacology, 2006, 31, 1241-1248.	5.4	222
75	Prolonged Kappa Opioid Receptor Phosphorylation Mediated by G-protein Receptor Kinase Underlies Sustained Analgesic Tolerance. Journal of Biological Chemistry, 2004, 279, 1810-1818.	3.4	98
76	Neuropathic Pain Activates the Endogenous Â Opioid System in Mouse Spinal Cord and Induces Opioid Receptor Tolerance. Journal of Neuroscience, 2004, 24, 4576-4584.	3.6	143
77	Phosphorylation of a Carboxyl-terminal Serine within the Îº-Opioid Receptor Produces Desensitization and Internalization. Journal of Biological Chemistry, 2003, 278, 34631-34640.	3.4	84
78	Îº Opioid Receptor Antagonism and Prodynorphin Gene Disruption Block Stress-Induced Behavioral Responses. Journal of Neuroscience, 2003, 23, 5674-5683.	3.6	449
79	8-Carboxamidocyclazocine: A Long-Acting, Novel Benzomorphan. Journal of Pharmacology and Experimental Therapeutics, 2002, 302, 374-380.	2.5	28
80	Tyrosine Phosphorylation of the Î¼-Opioid Receptor Regulates Agonist Intrinsic Efficacy. Molecular Pharmacology, 2001, 59, 1360-1368.	2.3	27
81	Regulation of Opioid Receptor Function by Chronic Agonist Exposure: Constitutive Activity and Desensitization. Molecular Pharmacology, 2001, 60, 20-25.	2.3	66
82	Tyrosine Phosphorylation of the Îº-Opioid Receptor Regulates Agonist Efficacy. Journal of Biological Chemistry, 2000, 275, 38281-38285.	3.4	18